Published in Medical Letter on the CDC and FDA, June 21st, 2006
The study demonstrated that Aranesp dosed every 2 weeks resulted in similar clinical efficacy as Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.
"Results of this study, the largest, randomized head-to-head comparison of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.